The objective of the University of Chicago training program in Basic Medical Oncology is to provide an outstanding interdisciplinary research training environment for postdoctoral fellows who have completed internal medicine residency training in order to prepare them for research-intensive careers in academia, government, industry and community based practices. Candidates for T32 training are recruited from the ACGME-accredited hematology/oncology training in the Section of Hematology/Oncology within our Department of Medicine with the expectation that candidates for T32 training will complete one clinical year funded by the hospital and then have a minimum of two or three years of research training under the proposed training grant depending on whether they perform patient-oriented research or fundamental basic/translational/population research. The direction of the program ? provision of multidisciplinary, structured, career development, advising and learning opportunities in cancer research ? has not changed since the program's inception, but we have continued to evolve the program in response to a national need to develop and/or enhance research training opportunities for individuals from diverse backgrounds interested in team science and translational research. There are several unique structural elements in the research training proposed: 1) access to a diverse population of cancer patients; 2) training under the guidance of multidiciplinary research preceptor(s) within a robust scientific environment that provides innovative scientific approaches, tools and technologies; 3) specific educational pathways in the form of course work and special seminars leading to a Masters degree from any relevant unit in the University; and 4) service learning opportunities to improve health equity in our catchment area on the Southside of Chicago and across the globe. The 33 Senior and 22 Clinical/Junior research training faculty preceptors have NIH or equivalent peer- reviewed funding, interact on a number of collaborative research and training efforts and are well qualified to serve as potential mentors for the six trainees per year participating in this T32 program. In the proposed grant period, we shall continue the successful elements of the program in Clinical Pharmacology, Genomics and Immunotherapy. At the same time, we shall enhance the curricular offerings by providing coursework in emerging areas of cancer research including Epigenetics, Metabolomics, Medical Informatics, Quality of Care, Implementation Science and Global Cancer Research. Our extensive inpatient and outpatient facilities promote a comprehensive clinical training experience, while our research laboratories allow for the acquisition of basic research skills. In addition, our diverse populations on the Southside of Chicago and our global partners will provide learning opportunities in community engaged research locally and at International sites to advance novel interventions to reduce the global burden of cancer. With the rapid pace of scientific advancement, a well trained oncology work force as proposed in this training program remains a wise investment for the nation.

Public Health Relevance

The objective of the training program in Basic Medical Oncology at the University of Chicago is to provide an outstanding interdisciplinary research training environment for clinician postdoctoral fellows who have completed internal medicine residency training. Physicians completing our training program will enter the oncology work force as socially responsible citizens who are prepared to lead cancer-focused research teams in academia, government, industry or community settings.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Schmidt, Michael K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
West, Allison H; Blazer, Kathleen R; Stoll, Jessica et al. (2018) Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer 17:495-505
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Veneris, Jennifer Taylor; Darcy, Kathleen M; Mhawech-Fauceglia, Paulette et al. (2017) High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol 146:153-160
Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2017) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer 15:207-212
Curran, Emily; Chen, Xiufen; Corrales, Leticia et al. (2016) STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep 15:2357-66
Sweis, Randy F; Ratain, Mark J (2016) Reply to T.A. Yap et al. J Clin Oncol 34:2432-3
Pettit, Kristen; Stock, Wendy; Walter, Roland B (2016) Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma 57:1527-33
Brewer, Jamie R; Morrison, Gladys; Dolan, M Eileen et al. (2016) Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol 140:176-83
Sweis, Randy F; Drazer, Michael W; Ratain, Mark J (2016) Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol 34:369-74
Bestvina, Christine M; Fleming, Gini F (2016) Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist 21:1250-1259

Showing the most recent 10 out of 59 publications